COSCIENS Biopharma Inc T.AEZ

Primary Symbol: T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc

Bullboard Posts

Comment by newdaydawningon Oct 13, 2015 9:36pm

123 Views

Post# 24188810

RE:RE:492,473,877

A 1-for-20 share consolidation seems plausible, but it will pizz off a lot of shareholders. Little wonder the selling continues. The reverse split may allow AEZ to keep its NAZ listing, but it will also open up a huge downside. I would wait until well after the consolidation to buy AEZ.

slagheap wrote: The llisting requirements for the NAZ include a US$35m minimum market cap. Today the m/c for AEZS was US$36.4m which is barely adequate. I expect the m/c to be closer to US$40m when the deadline is reached in December and will include a reverse split which looks to be about 20-1. An o/s of 25-30m sets them up for the next dilution a year from now at the earliest.

Bullboard Posts

A Look into the Future of Chronic Pain Management